[
 {
  "title": "History and Development of Cancer Treatments",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The history of cancer treatment starts with chemotherapy, radiation, and surgical therapy. These methodologies seemed to have leveled off. The timeline of advancements from when the War on Cancer was declared in the 1970s, through the sequencing of the entire human genome, to today is discussed. The topic of immunotherapy, a recent development in cancer therapy, is explored. A different approach to cancer that attacks all the essential pillars of cancer growth and survival is proposed.",
  "content_length": 490,
  "content_tokens": 90,
  "embedding": []
 },
 {
  "title": "Role of CRISPR and Other Therapies in Cancer Treatment",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The roles of CRISPR and other potentially over-hyped therapies with respect to cancer are discussed. The potential of stem cell therapy is also touched upon.",
  "content_length": 157,
  "content_tokens": 32,
  "embedding": []
 },
 {
  "title": "Liquid Biopsies and Cancer",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Liquid biopsies are discussed as a therapeutic monitoring tool in cancer treatment.",
  "content_length": 83,
  "content_tokens": 15,
  "embedding": []
 },
 {
  "title": "Vitamin D, Sun Exposure, and Melanoma",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The role of vitamin D and sun exposure in melanoma is discussed. The potential benefits and risks of vitamin D supplements are also explored.",
  "content_length": 141,
  "content_tokens": 27,
  "embedding": []
 },
 {
  "title": "Aging and Cancer",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The relationship between aging and cancer is discussed, exploring the question of whether cancer is inevitable as we age.",
  "content_length": 121,
  "content_tokens": 21,
  "embedding": []
 },
 {
  "title": "Insights on Alzheimer’s disease, cancer, exercise, nutrition, and fasting",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Latest insights on Alzheimer’s disease, cancer, exercise, nutrition, and fasting.",
  "content_length": 81,
  "content_tokens": 18,
  "embedding": []
 },
 {
  "title": "Impact of stress on physical and emotional health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The impact of stress on our physical and emotional health.",
  "content_length": 58,
  "content_tokens": 11,
  "embedding": []
 },
 {
  "title": "Optimizing brain health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Optimizing brain health: Alzheimer's disease risk factors, APOE, prevention strategies, and more.",
  "content_length": 97,
  "content_tokens": 22,
  "embedding": []
 },
 {
  "title": "Training principles for longevity",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Training principles for longevity.",
  "content_length": 34,
  "content_tokens": 5,
  "embedding": []
 },
 {
  "title": "Preventing cardiovascular disease",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Preventing cardiovascular disease: the latest in diagnostic imaging, blood pressure, metabolic health, and more.",
  "content_length": 112,
  "content_tokens": 21,
  "embedding": []
 },
 {
  "title": "Pros and cons of GLP-1 weight loss drugs and metformin",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent.",
  "content_length": 81,
  "content_tokens": 23,
  "embedding": []
 },
 {
  "title": "Overcoming trauma and living a meaningful life",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Overcoming trauma, finding inner peace, and living a meaningful and fulfilling life.",
  "content_length": 84,
  "content_tokens": 16,
  "embedding": []
 },
 {
  "title": "The history of the cell, cell therapy, and gene therapy",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The history of the cell, cell therapy, gene therapy, and more.",
  "content_length": 62,
  "content_tokens": 15,
  "embedding": []
 },
 {
  "title": "Cancer treatment advancements",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Keith Flaherty, director of clinical research and targeted cancer therapy at Massachusetts General Hospital, shares his vast wealth of knowledge in cancer starting with the history of treatment from chemotherapy to radiation to surgical therapy and where those methodologies seemed to have leveled off. He also walks us through the timeline of advancements (and lack there of) from when the War on Cancer was declared in the 1970s, through the sequencing of the entire human genome, and all the way to today.",
  "content_length": 508,
  "content_tokens": 93,
  "embedding": []
 },
 {
  "title": "Immunotherapy in cancer treatment",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Keith dives into the topic of immunotherapy, probably the most exciting recent development in cancer therapy, and also provides us a rundown of his notion of a different approach to cancer that attacks all the essential pillars of cancer growth and survival.",
  "content_length": 258,
  "content_tokens": 46,
  "embedding": []
 },
 {
  "title": "Role of CRISPR and stem cell therapy in cancer treatment",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "We discuss the roles of CRISPR and other potentially over-hyped therapies with respect to cancer. We also touch on stem cell therapy a bit, as well as some other common cancer-related questions such as the role of vitamin D and sun exposure in melanoma, and much more.",
  "content_length": 268,
  "content_tokens": 59,
  "embedding": []
 },
 {
  "title": "Work-Life Balance and Health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Work/life balance has been “off the rails” in terms of working long hours and being over committed and trying to juggle way too many things.",
  "content_length": 140,
  "content_tokens": 33,
  "embedding": []
 },
 {
  "title": "Medicine as a Career and Health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Medicine as a career, limitations of the med school teaching approach, and the dynamic and accelerating field of medicine and technology. The path to “academic success”, non-academic clinical success, it’s still relatively unperturbed compared to so many other paths outside of medicine. The technology and wealth of knowledge is accelerating. Things like data generation, ability to produce high dimensional data, analyze it, try to make sense of it, raise hypotheses, test hypotheses, yet the cycle time is changing a lot, and the constituents that we now need to interact with are totally different.",
  "content_length": 602,
  "content_tokens": 122,
  "embedding": []
 },
 {
  "title": "Medical School Teaching Approach and Health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Medical school teaches information as fact. When talking to people about cancer as a career, he tells them, “look, it’s so simple to find the boundary between what’s known and not known. There’s so much out there we don’t know and in any area of trying to understand physiology, pathophysiology, in the mode of cancer, you will so quickly get to that frontier.”",
  "content_length": 361,
  "content_tokens": 90,
  "embedding": []
 },
 {
  "title": "Chemotherapy and Health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "It’s actually not hard to kill a cancer cell, it’s actually very easy to kill a cancer cell. Problem is, they kill everything perfectly. The arbitrage is the following… it has to kill cancer, and almost kill (but not kill), non-cancer cells. That’s a narrow subset of things. And most of these things are targeting DNA which means they’re targeting things that grow (i.e., hair loss from chemo). Side effects of chemo: Hair loss, Sores in the mouth, Brittle nails, Rapidly dividing bone marrow cells.",
  "content_length": 500,
  "content_tokens": 125,
  "embedding": []
 },
 {
  "title": "Cancer Treatment and Health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Nixon declared the War on Cancer in 1971. If you look at ten year survival for metastatic solid organ tumor from 1974 until 10 years ago… Seminoma testicular cancer and GIST cancer were just about the only success stories. But if a woman had metastatic breast cancer in 1971, and a woman had metastatic breast cancer 40 years later there is shockingly little difference ⇒ Median survival extensions of maybe six months to twelve months.",
  "content_length": 436,
  "content_tokens": 88,
  "embedding": []
 },
 {
  "title": "Cancer Development and Health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "For a cancer cell to even exist, it has to have overcome a heck of a lot to get to be clinically relevant… Many of the common cancers (breast, colon, prostate, lung, pancreatic cancer) are perturbed at best by conventional chemotherapy. “Some sub populations of those cancer cells will slow down and die with conventional chemotherapy, but many of them are pre-wired. They were hardy to begin with. They got there through a hard earned evolution under selective pressure of the immune system and adverse metabolic environment, and they used all the tricks up their sleeve to reprogram themselves to be able to survive in these harsh environments. You throw in another harsh environment reagent in the form of chemo, not surprisingly, these things were already basically hardwired to be able to survive yet another insult.”",
  "content_length": 822,
  "content_tokens": 167,
  "embedding": []
 },
 {
  "title": "Radiation and Health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Radiation is limited because it’s not systemic. A great tool to locally control cancer. But now you’ve basically reached an asymptote at the two of the three pillars. The 3 pillars of treating cancer are chemo, radiation, and surgery.",
  "content_length": 234,
  "content_tokens": 56,
  "embedding": []
 },
 {
  "title": "Surgery and Health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Surgery is the third pillar for trying to treat cancer (and it may also asymptote). Example: Whipple procedure—Removing the head of the pancreas–One of the most complicated surgical procedures for cancer. That was an operation that used to carry a 50%, 30-day mortality (meaning you had a 50% chance of living through the surgery and the postoperative course). Today that’s 0.1% mortality at 30 days. But long term survival is still abysmal.",
  "content_length": 441,
  "content_tokens": 105,
  "embedding": []
 },
 {
  "title": "Cure Rate of Solid Tumors and Health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The cure rate of solid tumors that are amenable to surgery has never been less than 40% in Keith’s career (maybe even 50% he says). Circulating cells in the blood have a hard time surviving. People think about a circulating cancer cell, and assume that it’s going to succeed, but it’s super hard to launch a cancer cell into the blood stream and actually have it find fertile soil.",
  "content_length": 381,
  "content_tokens": 88,
  "embedding": []
 },
 {
  "title": "Gene Sequencing and Health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "It’s the late ’90s and the scientific community is on the cusp of fully sequencing the human genome. We certainly understood that cancers are initiated by genetic mutations (some genes that suppress tumors, and some genes that promote tumors). A justification for doing whole genome sequencing in cancer was that we didn’t know what that sequence might look like across cancer. We didn’t know what the spectrum of genetically simple to genetically complex cancers was.",
  "content_length": 468,
  "content_tokens": 94,
  "embedding": []
 },
 {
  "title": "Genetic Inheritance and Cancer",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Nearly all of the genetically inherited cancer types that people are familiar with, come from having an inherited alteration that partially or completely disables a tumor suppressor gene. The activation of a tumor promoting gene (oncogene) is also a factor. Even in the most genetically simple cases, there are genetic alterations that can dial the combination lock in the right way, but the simplest genetic defined cancers almost certainly have then an “epigenetic” mutation alteration change as well where they occupy a different state of development compared to their normal cell counterparts.",
  "content_length": 597,
  "content_tokens": 110,
  "embedding": []
 },
 {
  "title": "Cancer Treatment and HIV Case Study",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "At the time Keith was finishing school, AZTs were starting to be used to treat HIV/AIDS successfully. Keith said his talking point was…“we need to find, in cancer, as many ‘AZTs’ as we need, as the initial foot in the door. We know we’re going to receive resistance in this much more complex entity that is a human cell that’s gone rogue, versus relatively simple virus. But it’s when we poke it with the AZT equivalents, we’re going to learn about how it is that it tries to adapt. That’s going to allow us to develop rational combination therapy exactly the way the HIV field does.”",
  "content_length": 584,
  "content_tokens": 147,
  "embedding": []
 },
 {
  "title": "Cancer Immunotherapy",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Cancer immunotherapy is another idea for systemic type of therapy. Once the mutations happen to cancer, they cease to be purely self…they start to display a little bit of non-self characteristic. We have this branch of the immune system that is staggering effective at eradicating non-self things (namely viruses). In the ’90s, we had a number of people making progress using immunotherapy.",
  "content_length": 390,
  "content_tokens": 83,
  "embedding": []
 },
 {
  "title": "MHC Complexes and Cancer Cloaking Mechanisms",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Successful cancers have to find cloaking mechanisms. They will not succeed otherwise. Major histocompatibility complex (MHC) are cell surface proteins that have the opportunity to sample internal contents, protein fragments, etc. MHC Class 1 and Class 2 are inherited from our parents. Class one and class two can hold different size protein fragments. Class 2 can hold longer peptides that can see potentially bigger repertoire than Class 1.",
  "content_length": 442,
  "content_tokens": 86,
  "embedding": []
 },
 {
  "title": "Survival of Cancers",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "In trying to understand the features of cells that will survive the onslaught of an activated immune system after checkpoint therapy (e.g., PD-1 or CTLA-4), some patients will clear their tumor, and they’re cured. There are those who don’t clear their tumor, and they’re not cured (i.e., complete remission with a relapse or just a partial remission). This activated immune system has just been raging, yet many cancers survive… how do the cancers survive? They start to dial down their MHC complex expression through genetic and epigenetic means… just enough to satisfy the NK cells, but no more.",
  "content_length": 597,
  "content_tokens": 133,
  "embedding": []
 },
 {
  "title": "Comparative Biology of Cancer",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Pancreatic cancer and glioblastoma are examples of cancers that are not very immunogenic on the spectrum (i.e., meaning the immune system does not catch them and kill them very easily). At the time of diagnosis, if you take note of how much immune recognition is there and compare that to: how much does that relate to how long someone lives, how likely they are to respond to immunotherapy, how likely they are to respond to even to conventional chemotherapy.",
  "content_length": 460,
  "content_tokens": 98,
  "embedding": []
 },
 {
  "title": "Cancer Types and Heterogeneity",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Cancer can be splayed out into all types, and there’s heterogeneity within cancer types as well (e.g., not all lung cancers are the same). Some of these are aggressive tumors, they’re not being seen adequately, so they’re not being slowed by the immune system in their evolution.",
  "content_length": 279,
  "content_tokens": 67,
  "embedding": []
 },
 {
  "title": "Pancreatic Endocrine Cell Protection",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The protection of a pancreatic endocrine cell is a black box at the moment. The comparative biology questions are: What are the building blocks, genetic, epigenetic, the metabolic features, and how did each of these tumors assemble themselves to be able to accomplish the various behaviors of cancer that make them lethal?",
  "content_length": 322,
  "content_tokens": 62,
  "embedding": []
 },
 {
  "title": "Hormonally Driven Cancers",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Hormonally driven cancers are a unique entity. Examples include prostate cancer which is almost all hormonally driven, at least at its outset, and it can evolve away from hormonal drive/dependence during its subsequent evolution. A significant portion of breast cancer, but not all, is hormonally driven.",
  "content_length": 304,
  "content_tokens": 62,
  "embedding": []
 },
 {
  "title": "Cancer Genome Atlas Project",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The Cancer Genome Atlas Project involved whole genome sequencing of large numbers of cancers. The big discovery was how commonly you will find, across cancer, driver genetic events (i.e., causative genetic alterations) in genes whose protein product regulates chromosomal wellbeing (i.e., epigenetic regulators).",
  "content_length": 312,
  "content_tokens": 60,
  "embedding": []
 },
 {
  "title": "Defining Targeted Therapy",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Targeted therapy is simply that we “knew what we were doing from the beginning”. None of the conventional chemotherapy drugs were known to be DNA binding or designed and engineered to be them. But the target product profile, was spec’d out for everything that we call targeted therapy.",
  "content_length": 285,
  "content_tokens": 61,
  "embedding": []
 },
 {
  "title": "Tumor Protein P53",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "TP53 is the most famous tumor suppressor gene. 50% of cancers have genetic aberration of P53. Partly it’s just a really large gene, so you can pick up mutations in it seemingly relatively easily. But it’s also a master regulator. Tons of translated proteins that interact with the protein product P53.",
  "content_length": 301,
  "content_tokens": 71,
  "embedding": []
 },
 {
  "title": "Activated Oncogenes",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The “activated side” is where most of the career has been spent. Epidermal growth factor receptor and HER2 were the early discovery/therapeutic translation exercises. To this day, we think is the biggest unit in terms of where the activating events happen. We have drugs now in the growth factor receptor, RAS, and RAS pathway system.",
  "content_length": 334,
  "content_tokens": 75,
  "embedding": []
 },
 {
  "title": "RAS Effector Pathways and Cancer",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "RAS activates other cascades, the two most famous are the MAP kinase pathway and the PI3 kinase pathway. 20% of cancers have PI3 kinase intrinsic mutations in one of the isoforms of PI3 kinase. This co-opting of the metabolic regulation pathway largely explains growth factor independence of cancers that have those mutations. However, these are metabolic pathways that are fundamental to normal cells as well. When you activate an oncogene in cancer, the downstream wiring diagram changes, and that pathway is now able to do more things than it could in its normal, non-mutated state.",
  "content_length": 585,
  "content_tokens": 124,
  "embedding": []
 },
 {
  "title": "Targeted Therapy and Oncogene Addiction",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The concept of targeted therapy was thought about in the early 2000s. This idea that by a cancer co-opting this one molecule, it’s actually now essentially using it to drive more components of cancer biology than you have thought in terms of the normal physiologic role of that molecule, and where there’s compensatory mechanisms and parallel processing that can happen in normal cells that make it not so dependent on that function of that one molecule.",
  "content_length": 454,
  "content_tokens": 92,
  "embedding": []
 },
 {
  "title": "Cancer Mutations",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "25+% of cancers have a RAS mutation. 20% of cancers have a PI3K mutation. 8% of cancers have a BRAF mutation. BRAF is intrinsic in the MAP Kinase Pathway. It’s the most popular point of mutation in that pathway. About 50% of melanomas have a BRAF mutation.",
  "content_length": 256,
  "content_tokens": 70,
  "embedding": []
 },
 {
  "title": "Phosphorylation and Cancer",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "When Ras itself is activated, it pushes RAF into a pair of molecules (dimers) and will facilitate their phosphorylation or activate molecular feature change that allows them to be active. Kinases are a form of enzyme whose job is to add a phosphate group to specific amino acid residues on its target. Phosphate residue additions are not the most important, but they’re a key facet of how the molecular machinery works inside of cells in terms of how to activate (or inactivate) these networks.",
  "content_length": 494,
  "content_tokens": 103,
  "embedding": []
 },
 {
  "title": "Fusion-driven Cancers",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Fusion-driven cancers, targeted therapy, and the Bcr-Abl/chronic myelogenous leukemia case study. BCR is stitched to ABL … it equates the Bcr-ABL translocation or fusion. You now have a new gene product of these two genetic components being stitched together that otherwise wouldn’t have been. When they come together, you crank up the expression of ABL kinase. The first-line therapy for most patients with chronic myelogenous leukemia: Bcr-Abl tyrosine-kinase inhibitors.",
  "content_length": 473,
  "content_tokens": 118,
  "embedding": []
 },
 {
  "title": "Point Mutations and Genetic Complexity in Cancer",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Point mutations occur in the sea of genetic complexity, with melanoma being an example. All BRAF mutations distribute across cancer types that are genetically complex, meaning there’s a lot of other genetic aberrations turning on and off other things. Fusion driven cancers seem to get a lot of juice out of that one genetic alteration.",
  "content_length": 336,
  "content_tokens": 67,
  "embedding": []
 },
 {
  "title": "First Kinase Inhibitors",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The first kinase inhibitors were created for CVD. There are about 600 kinases and they’re highly related, but then there’s some that are more distant cousins than others. If you try to inhibit a kinase, it’s pretty easy to pick up inhibitory activity against another kinase because of their relatedness. Imatinib, for example, the first ABL kinase inhibitor, was not just an ABL kinase inhibitor (it was also a c-Kit inhibitor for gastrointestinal stromal tumor).",
  "content_length": 463,
  "content_tokens": 111,
  "embedding": []
 },
 {
  "title": "Chronic Myelogenous Leukemia (CML) and Kinase Inhibitor",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Patients with CML were responding to therapy in a phase one trial. By the phase III trial, patients were having transformational responses. However, given enough time to evolve, it will pick up more alterations and the rate at which alterations are picked up accelerates also and patients die of an acute leukemia like death. In other words, given enough time, stable CML will become deadly cancer.",
  "content_length": 398,
  "content_tokens": 80,
  "embedding": []
 },
 {
  "title": "Targeted Therapy for Fusion-Driven Solid Tumors",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Even in solid tumors, you will find subsets of them that are driven by these translocation fusion events. They tend to be genetically simple where you get deep and durable responses. For example, HER2-positive breast cancer in a metastatic situation: Trastuzumab, the naked antibody, has the ability to help a metastatic breast cancer patient live longer for a period of time (several months).",
  "content_length": 393,
  "content_tokens": 84,
  "embedding": []
 },
 {
  "title": "Adjuvant Therapy",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Adjuvant therapy is additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy.",
  "content_length": 251,
  "content_tokens": 45,
  "embedding": []
 },
 {
  "title": "Advancing Melanoma Treatment with BRAF-MEK Combo Therapy",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Metastatic melanoma treated with BRAF inhibitor monotherapy showed 9 months improvement in overall survival. However, tumors were working their way right around the drug in the MAP kinase pathway. They were bypassing BRAF through c-RAF, most commonly. BRAF-MEK combination therapy showed overall survival improvement to be as big as the BRAF inhibitor monotherapy.",
  "content_length": 364,
  "content_tokens": 76,
  "embedding": []
 },
 {
  "title": "Fundamental Pillars of Cancer Growth and Survival",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "There are some fundamental pillars in growth and protection. We need a tool kit that “knows” which pillars they are hitting so we can stack them together. We need the activators of the immune system, we need the inhibitors of the activated oncogenes, we need the drugs that target epigenetic regulators, and we need the metabolic switch regulators.",
  "content_length": 348,
  "content_tokens": 74,
  "embedding": []
 },
 {
  "title": "Clinical Framework for Thinking About Cancer",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The likelihood of getting cancer is somewhere between ⅓ and ½ (depending on gender). There are a handful of things that are increasing our risk for cancer, such as smoking and insulin resistance and obesity. Early detection of cancer is crucial. If cancer exists, use therapies that go after multiple pillars simultaneously (i.e., immune system, epigenetic regulators, growth factor receptors, metabolic).",
  "content_length": 405,
  "content_tokens": 78,
  "embedding": []
 },
 {
  "title": "Biotech Environment and Cancer Treatments",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "60% of drugs coming in the cancer pipeline now come from small biotech companies. Big pharma outsourced its R&D to risk taking, venture-backed, highly-specialized, small biotech companies. The basic science, as you well know across all public, private domain, is in the public sector. The basic science, the stuff where you can’t guarantee any kind of return in terms of when you’re going to get an insight that you could turn into a potential therapy. We live in a world right now where 0.37% of rational combinations of two cancer therapeutics that are still in investigational territory are finding each other in clinical trials. We need a way to change that. And we need a way for drugs to be able to be married in life threatening cancer in a rapid, rapid fashion.",
  "content_length": 769,
  "content_tokens": 169,
  "embedding": []
 },
 {
  "title": "CRISPR and Tumor Suppression",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "On the tumor suppressor side, does CRISPR offer any role? This is gene therapy, you need to be able to deliver that to every last cancer cell. And how in the world do we do that? Is there a virus that can do this? Not currently. 20 years ago, at the dawn of Keith’s career, he though gene therapy was almost ready, but 20 years later, we still don’t have it.",
  "content_length": 358,
  "content_tokens": 92,
  "embedding": []
 },
 {
  "title": "Liquid Biopsies as a Therapeutic Monitoring Tool",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Is Keith bullish on liquid biopsies? “For sure”. What is a liquid biopsy? It’s a non-invasive, cancer screening technique. Types of liquid biopsies in cancer: Circulating tumor DNA (ctDNA), Circulating tumor cells (CTCs). Will liquid biopsies reduce the risk of physical harm to a patient, and psychological harm (via reduction in false positives)? Peter posits that If you could layer liquid biopsy on top of diffusion weighted imaging MRI, the best colonoscopy, the best mammography, etc…you can theoretically construct a point where you can catch every cancer prior to its clinical presentation.",
  "content_length": 598,
  "content_tokens": 137,
  "embedding": []
 },
 {
  "title": "Stem Cell Therapy: The Efficacy and Potential Risks",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Peter asks Keith about his opinion on stems cells. Peter says he has at least one patient using intravenous stem cell therapy. His symptoms have improved dramatically. But, given the lack of good evidence, Peter isn’t so sure the stem cells are that effective. And Peter is a little worried about the risk that the stem cells could acquire a life of their own (and presumably turn cancerous).",
  "content_length": 392,
  "content_tokens": 81,
  "embedding": []
 },
 {
  "title": "Aging and Cancer: Is Cancer Inevitable?",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "It’s impossible to deny the age-related association between age and cancer. Cancer rates rise monotonically until the ninth decade or so… If you’re 50 versus 60, versus 70, you leap frog up in risk. Almost exponentially, or at least quadratically, it’s not just linear.",
  "content_length": 269,
  "content_tokens": 67,
  "embedding": []
 },
 {
  "title": "Vitamin D Supplements, Sun Exposure, Melanoma, and Exercise",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The evidence that sun exposure and melanoma are associated in a causal way, from sun to melanoma, is strong. We also know that sun exposure increases the de Novo synthesis of Vitamin D in humans. We also know that, from an association perspective… Higher levels of Vitamin D port with good things happening… Low levels of Vitamin D port with bad things happening. This has led people to suggest that we should be supplementing with Vitamin D.",
  "content_length": 442,
  "content_tokens": 90,
  "embedding": []
 },
 {
  "title": "Vitamin D Supplementation",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Many doctors have historically normalized patient’s Vitamin D levels with supplements. However, multiple clinical trials are demonstrating that supplemental Vitamin D doesn’t really seem to help that much. The vitamin D that you take supplementary is not fixing the problem. The vitamin D that’s getting fixed in the sun is a proxy for the good thing happening in the sunlight. It’s like saying gray hair is a proxy of aging, dyeing your hair black or blonde isn’t fixing your aging.",
  "content_length": 483,
  "content_tokens": 103,
  "embedding": []
 },
 {
  "title": "Exercise and Vitamin D",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "The confounder is exercise. The huge confounder is all these people outside are exercising, and exercise (non sunlight or vit D) is what’s been giving them the benefit. Vitamin D is beneficial, but the exercise that people are doing while outside is transcribing more of the benefit. If you must exercise outdoors, avoid the middle of the day when the sun is most powerful. Do it in the early morning/evening.",
  "content_length": 409,
  "content_tokens": 91,
  "embedding": []
 },
 {
  "title": "Sun Exposure and Health",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "A study suggests that we might be engineered to get out in the sun and there must be benefits from it… but the question is… how much of the benefit is Vitamin D? And the other part of this is that there would be zero “evolutionary pressure” towards preventing from getting melanoma because our ancestors did not live long enough to develop it. In other words… [getting a lot of sun exposure] is a behavior that is maladapted for those who are going to live to be 60, 70, 80, 100 years old, but not maladaptive for people who are going to live to be 30 and die from predatory death or whatever the issue back in evolutionary time.",
  "content_length": 629,
  "content_tokens": 142,
  "embedding": []
 },
 {
  "title": "Indoor Exercise and Vitamin D Supplementation",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "If you could exercise indoors, never see the sunlight except through your window, and supplement Vitamin D… do you think you are doing as well, health-wise, as someone who does NOT supplement Vitamin D but exercises outdoors and attains the same Vitamin D level? The idea that there’s some other magical component of UV exposure. . .we lack the evidence to support that.",
  "content_length": 370,
  "content_tokens": 78,
  "embedding": []
 },
 {
  "title": "Importance of Understanding Patient's Perspective",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "You need to understand to the best of your ability how people’s worlds turn, you really need to develop that understanding. Otherwise you cannot be an effective constituent, you can’t be an advocate within your field for your current patients, for the future patients, next generation patients, patients worldwide who you’re trying to advocate for, you can’t do that if you don’t understand what’s constraining on the other side.",
  "content_length": 429,
  "content_tokens": 96,
  "embedding": []
 },
 {
  "title": "Role of Clinical Investigators in Biomedical Companies",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "Clinical investigators didn’t have those opportunities. Should they have those opportunities? Well, you can imagine from what I’ve just said, absolutely. These are super bright people who have accomplished in multiple dimensions, but if they are not on MD, or MD-PhD, or even straight PhD in biomedical research, let’s say in cancer, there’s a component that they don’t see. Where if you’re able to provide that as a single person around a board of eight, that contribution can be disproportionate.",
  "content_length": 498,
  "content_tokens": 115,
  "embedding": []
 },
 {
  "title": "Need for More Stakeholder Representation in Biomedical Research",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "As cancer science has become so much more translational, the opportunity unfolded for me and I think it would be of a major benefit to the field for the private sector basically to engage more voices at the table of those who are involved in the truly applied science down to the patient level.",
  "content_length": 294,
  "content_tokens": 57,
  "embedding": []
 },
 {
  "title": "Importance of Fiduciary Responsibility in Biotech/Pharma Companies",
  "date": "July 15, 2019",
  "context": "Preventing Chronic Disease",
  "people": "Peter Attia",
  "content": "All of these companies, every single one of them, every company I’ve interacted with in biotech/Pharma, they will all say that they are trying to move the needle for patients. This is their stated goal and I believed them. How do you do that if you don’t have in the room exactly as you say, invested responsible leaders of the company in the case of the board who actually have career long skin in that game?",
  "content_length": 409,
  "content_tokens": 92,
  "embedding": []
 }
]